Free Trial

XTL Biopharmaceuticals Q2 2023 Earnings Report

XTL Biopharmaceuticals EPS Results

Actual EPS
-$0.07
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

XTL Biopharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

XTL Biopharmaceuticals Announcement Details

Quarter
Q2 2023
Time
N/A

Conference Call Resources

XTL Biopharmaceuticals Earnings Headlines

A tiny 1% move could have you targeting triple-digit gains with Gamma Pockets
What if you knew exactly how to spot certain stocks Wall Street could be forced to buy… and you had a special trading setup for steering their moves into an opportunity? I bet you’d find that thrilling! Well, thanks to an unusual anomaly in the options markets, regular traders like me and you can do exactly that with the ‘Gamma Pockets’ You see, spotting these Gamma Pockets has changed the entire way I look at the market because we can now target wins like this in just 5 days or less…
XTL Biopharmaceuticals Ltd (XTLB)
XTL Biopharmaceuticals Ltd XTLB
See More XTL Biopharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like XTL Biopharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on XTL Biopharmaceuticals and other key companies, straight to your email.

About XTL Biopharmaceuticals

XTL Biopharmaceuticals (NASDAQ:XTLB) engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. Its pipeline includes hCDR1 and Erythropoietin. The company was founded on March 9, 1993 and is headquartered in Ramat Gan, Israel.

View XTL Biopharmaceuticals Profile

More Earnings Resources from MarketBeat